Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS

Blood

Volumn 124, Issue 4, 2014, Pages 611-622

  Proulle, Valerie ^a   Furie, Richard A ^b   Merrill Skoloff, Glenn ^a   Furie, Barbara C ^a   Furie, Bruce ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Northwell Health   (United States)

^c Center for Life Science   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CALCIUM; EPTIFIBATIDE; FIBRIN; INTERCELLULAR ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CALCIUM MOBILIZATION; CELL ACTIVATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRIN FORMATION; HUMAN; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THROMBOCYTE ACTIVATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS; THROMBUS; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; BLOOD PLATELETS; BLOTTING, WESTERN; CELL MEMBRANE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM; FIBRIN; FIBRINOGEN; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MICE; MICE, INBRED C57BL; PLATELET ACTIVATION; THROMBOSIS;

EID: 84904906141     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-554980     Document Type: Article

References (59)

1. de Groot PG, Urbanus RT. The significance of autoantibodies against b2-glycoprotein I. Blood. 2012;120(2):266-274.
2. Willis R, Harris EN, Pierangeli SS. Pathogenesis of the antiphospholipid syndrome. Semin Thromb Hemost. 2012;38(4):305-321.
3. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7(6):330-339.
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A. 1990;87(11):4120-4124.
5. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A. 1998;95(26): 15542-15546. (Pubitemid 29018735)
6. de Laat B, de Groot PG. Autoantibodies directed against domain I of beta2-glycoprotein I. Curr Rheumatol Rep. 2011;13(1):70-76.
7. 2- Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood. 2011;117(12):3453-3459.
8. Girardi G, Mackman N. Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule. Lupus. 2008; 17(10):931-936.
9. Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood. 2007;110(7):2423-2431. (Pubitemid 47523163)
10. Shi T, Giannakopoulos B, Yan X, et al. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum. 2006;54(8):2558-2567. (Pubitemid 44205017)
11. Pennings MT, Derksen RH, van Lummel M, et al. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 29. J Thromb Haemost. 2007;5(2):369-377. (Pubitemid 46139463)
12. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 29. J Biol Chem. 2003; 278(36):33831-33838. (Pubitemid 37553217)
13. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood. 1991;78(11):2894-2899.
14. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
15. Falati S, Gross P, Merrill-Skoloff G, Furie BC, Furie B. Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse. Nat Med. 2002;8(10): 1175-1181.
16. Jasuja R, Passam FH, Kennedy DR, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents. J Clin Invest. 2012;122(6):2104-2113.
17. Dubois C, Panicot-Dubois L, Gainor JF, Furie BC, Furie B. Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J Clin Invest. 2007;117(4):953-960. (Pubitemid 46556751)
18. Atkinson BT, Jasuja R, Chen VM, Nandivada P, Furie B, Furie BC. Laser-induced endothelial cell activation supports fibrin formation. Blood. 2010; 116(22):4675-4683.
19. Döring Y, Hurst J, Lorenz M, et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology. 2010;215(3):230-241.
20. Romay-Penabad Z, Aguilar-Valenzuela R, Urbanus RT, et al. Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome. Blood. 2011;117(4):1408-1414.
21. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009;114(14): 3074-3083.
22. Ramesh S, Morrell CN, Tarango C, et al. Antiphospholipid antibodies promote leukocyteendothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest. 2011;121(1):120-131.
23. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2′. J Thromb Haemost. 2008;6(8): 1405-1412. (Pubitemid 352016322)
24. Agostinis C, Biffi S, Garrovo C, et al. In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions. Blood. 2011;118(15): 4231-4238.
25. Pober JS, Gimbrone MA Jr, Lapierre LA, et al. Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol. 1986; 137(6):1893-1896. (Pubitemid 16021101)
26. Diacovo TG, deFougerolles AR, Bainton DF, Springer TA. A functional integrin ligand on the surface of platelets: intercellular adhesion molecule-2. J Clin Invest. 1994;94(3):1243-1251. (Pubitemid 24286469)
27. Gross PL, Furie BC, Merrill-Skoloff G, Chou J, Furie B. Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development. J Leukoc Biol. 2005;78(6): 1318-1326. (Pubitemid 41779238)
28. Simantov R, LaSala JM, Lo SK, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995; 96(5):2211-2219.
29. Del Papa N, Guidali L, Sala A, et al. Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40(3): 551-561.
30. Del Papa N, Raschi E, Catelli L, et al. Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. Am J Reprod Immunol. 1997;38(3):212-217. (Pubitemid 27379534)
31. McCrae KR, DeMichele A, Samuels P, et al. Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol. 1991;79(4):595-605.
32. George J, Blank M, Levy Y, et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation. 1998;97(9):900-906. (Pubitemid 28113929)
33. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99(15):1997-2002. (Pubitemid 29183897)
34. Colasanti T, Alessandri C, Capozzi A, et al. Autoantibodies specific to a peptide of b2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood. 2012;120(16):3360-3370.
35. Allen KL, Hamik A, Jain MK, McCrae KR. Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors. Blood. 2011;117(23): 6383-6391.
36. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-β2 glycoprotein I antibodies. Blood. 2012;119(3): 884-893.
37. Dunoyer-Geindre S, de Moerloose P, Galve-de Rochemonteix B, Reber G, Kruithof EK. NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)- glycoprotein 1 antibodies. Thromb Haemost. 2002;88(5):851-857. (Pubitemid 35345346)
38. Meroni PL, Raschi E, Testoni C, Borghi MO. Endothelial cell activation by antiphospholipid antibodies. Clin Immunol. 2004;112(2):169-174. (Pubitemid 38881482)
39. Satta N, Dunoyer-Geindre S, Reber G, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood. 2007;109(4):1507-1514. (Pubitemid 46239583)
40. Raschi E, Borghi MO, Grossi C, Broggini V, Pierangeli S, Meroni PL. Toll-like receptors: another player in the pathogenesis of the antiphospholipid syndrome. Lupus. 2008;17(10): 937-942.
41. Ma K, Simantov R, Zhang JC, Silverstein R, Hajjar KA, McCrae KR. High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by annexin II. J Biol Chem. 2000; 275(20):15541-15548. (Pubitemid 30337288)
42. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis. 2007;66(10):1327-1333. (Pubitemid 47492476)
43. Kolyada A, Porter A, Beglova N. Inhibition of thrombotic properties of persistent autoimmune anti-B2GPI antibodies in the mouse model of antiphospholipid syndrome. Blood. 2014;123(7): 1090-1097.
44. Jankowski M, Vreys I, Wittevrongel C, et al. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood. 2003;101(1):157-162. (Pubitemid 36025902)
45. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005;106(7): 2340-2346. (Pubitemid 41510805)
46. Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN. Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies. Circulation. 1996; 94(7):1746-1751. (Pubitemid 26320284)
47. Pierangeli SS, Harris EN. Antiphospholipid antibodies in an in vivo thrombosis model in mice. Lupus. 1994;3(4):247-251. (Pubitemid 24277035)
48. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001;88(2): 245-250. (Pubitemid 32147315)
49. Gharavi AE, Pierangeli SS, Colden-Stanfield M, Liu XW, Espinola RG, Harris EN. GDKV-induced antiphospholipid antibodies enhance thrombosis and activate endothelial cells in vivo and in vitro. J Immunol. 1999;163(5):2922- 2927. (Pubitemid 29399224)
50. Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48(11): 3272-3279. (Pubitemid 37409342)
51. Pierangeli SS, Liu X, Espinola R, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost. 2000;84(3):388-395.
52. Espinola RG, Liu X, Colden-Stanfield M, Hall J, Harris EN, Pierangeli SS. E-Selectin mediates pathogenic effects of antiphospholipid antibodies. J Thromb Haemost. 2003;1(4):843-848.
53. Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost. 2000;84(5):742-746.
54. Frijns R, Fijnheer R, Schiel A, Donders R, Sixma J, Derksen R. Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol. 2001;28(3):514-519. (Pubitemid 32202652)
55. Kaplanski G, Cacoub P, Farnarier C, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum. 2000; 43(1):55-64. (Pubitemid 30368213)
56. Dignat-George F, Camoin-Jau L, Sabatier F, et al. Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. Thromb Haemost. 2004;91(4):667-673. (Pubitemid 38477445)
57. Vandendries ER, Hamilton JR, Coughlin SR, Furie B, Furie BC. Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosis. Proc Natl Acad Sci U S A. 2007;104(1):288-292. (Pubitemid 46068024)
58. Jasuja R, Furie B, Furie BC. Endothelium-derived but not platelet-derived protein disulfide isomerase is required for thrombus formation in vivo. Blood. 2010;116(22):4665-4674.
59. Cho J, Kennedy DR, Lin L, et al. Protein disulfide isomerase capture during thrombus formation in vivo depends on the presence of β3 integrins. Blood. 2012;120(3):647-655.